Abstract: Background: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the spine, which mainly invades the sacroiliac joint, spine, and large joints near the trunk, leading to fibrous and skeletal ankylosis and deformity, and can cause damage to the eyes, lung, cardiovascular, kidney and other organs. Chinese herbal formulas (CHF) is an important interventions of Traditional Chinese Medicine (TCM), and CHFs combined with western medicine are widely used in clinical practice to treat AS.
Methods: Eight databases will be systematically retrieved from their inceptions to March 2021. Only randomized controlled trials (RCTs) of CHFs combined with western medicine for AS treatment will meet the inclusion criteria. The primary outcomes we focus on include clinical effectiveness rate, TCM syndrome score, TCM symptom score, Bath ankylosing spondylitis disease activity index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), chest expansion, nocturnal spinal pain, adverse reactions, erythrocyte sedimentation rate (ESR), and C protein response (CRP). The research screening, data extraction, and risk of bias assessment will be performed independently by 2 researchers, and divergence will be solved by a third researcher. Revman 5.3 software will be used for meta-analysis. The confidence of evidence will be graded using grading of recommendations assessment, development, and evaluation (GRADE) algorithm and methodological quality will be assessed adopting risk of bias in systematic reviews (ROBIS).
Results: This systematic review (SR) will provide evidence-based medical evidence for AS therapy by CHF combined with western medicine and we will submit the findings of this SR for peer-review publication.
Conclusions: This SR will provide latest and updated summary proof for assessing the effectiveness and safety of CHF combined with western medicine for AS.
Registration Number: INPLASY 202150089.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 2015;15:489.
Golder V, Schachna L. Ankylosing spondylitis: an update. Aust Fam Physician 2013;42:780–4.
Hanson A, Brown MA. Genetics and the causes of ankylosing spondylitis. Rheum Dis Clin North Am 2017;43:401–14.
Millner JR, Barron JS, Beinke KM, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum 2016;45:411–27.
Blair HA. Secukinumab: a review in ankylosing spondylitis. Drugs 2019;79:433–43.
Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014;48-49:128–33.
Regnaux JP, Davergne T, Palazzo C, et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev 2019;10:CD011321.
Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology,;1; pathogenesis,;1; and treatments. Bone Res 2019;7:22.
Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis: recent advances and future directions. Nat Rev Rheumatol 2017;13:359–67.
Fiorillo MT, Haroon N, Ciccia F, et al. Editorial: ankylosing spondylitis and related immune-mediated disorders. Front Immunol 2019;10:1232.
Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650–7.
Xi Y, Jiang T, Chaurasiya B, et al. Advances in nanomedicine for the treatment of ankylosing spondylitis. Int J Nanomedicine 2019;14:8521–42.
Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford) 2018;57: (suppl 6): vi4–9.
Giovannopoulou E, Gkasdaris G, Kapetanakis S, et al. Ankylosing spondylitis and pregnancy: a literature review. Curr Rheumatol Rev 2017;13:162–9.
Metzgar MM. Autoimmune conditions: ankylosing spondylitis. FP Essent 2020;494:30–5.
Acar Y, Ilçin N, Gürpinar B, et al. Core stability and balance in patients with ankylosing spondylitis. Rheumatol Int 2019;39:1389–96.
Machado MA, Moura CS, Ferré F, et al. Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica 2016;50:50.
Bansal P, Rich T. Dural ectasias in ankylosing spondylitis. Clin Rheumatol 2021;40:421–2.
Leone A, Marino M, Dell’Atti C, et al. Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int 2016;36:1335–46.
Magrey M, Ritchlin C. Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. Curr Opin Rheumatol 2019;31:109–17.
Motta F, Carena MC, Selmi C, et al. MicroRNAs in ankylosing spondylitis: function, potential and challenges. J Transl Autoimmun 2020;3:100050.
Zhang D, Liu W, Yang H, et al. [Clinical review of ankylosing spondylitis treated with acupuncture and medicine]. Zhongguo Zhen Jiu 2016;36:893–6.
Xie D, Huang L, Zhao G, et al. Dissecting the underlying pharmaceutical mechanism of Chinese traditional medicine Yun-Pi-Yi-Shen-Tong-Du-Tang acting on ankylosing spondylitis through systems biology approaches. Sci Rep 2017;7:13436.
Zhou YY, Lin JH, Huang RY, et al. Treatment of ankylosing spondylitis with a Bushen-Qiangdu-Zhilv decoction: a case report with a 3-year follow-up. Altern Ther Health Med 2016;22: (suppl 1): 36–40.
Wang Y, Xiao X. Clinical efficacy of modified Yanghe decoction in ankylosing spondylitis: a randomized controlled trial. Med Sci Monit 2018;24:2912–8.
Pang L, Zhang H, Lü X, et al. Preventive and therapeutic effectiveness of Sanfu acupoint herbal patching for chronic obstructive pulmonary disease at stable stages: a systematic review and Meta-analysis. J Tradit Chin Med 2020;40:530–49.
Pang LJ, Liu JP, Lv XD. Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis protocol. Medicine (Baltimore) 2019;98:e16325.
Zhang HY, Pang LJ, Lv XD, et al. Multiple traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis: a protocol for systematic review and meta-analysis of overview. Medicine (Baltimore) 2020;99:e22396.
Moher D, Shamseer L, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
Clark HD, Wells GA, McAlister HuSC, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448–52.
Pollock A, Farmer SE, Brady MC, et al. An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews. J Clin Epidemiol 2016;70:106–10.
Whiting P, Savović J, Higgins JP, et al. ROBIS group. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 2016;69:225–34.
Zhang X, Tan R, Lam WC, et al. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med 2020;48:1279–313.
Zão A, Cantista P. The role of land and aquatic exercise in ankylosing spondylitis: a systematic review. Rheumatol Int 2017;37:1979–90.
Sun YY, Cui HJ, Dong JN, et al. Randomized, controlled trial: efficacy of ultrasound and exercise in patients with ankylosing spondylitis. Altern Ther Health Med 2018;24:30–4.
Processing Request
No Comments.